Myasthenia Gravis Treatment Market - By Treatment Type, By Disease Type, By Distribution Channel - Global Forecast, 2025 - 2034

Myasthenia Gravis Treatment Market Size

The global myasthenia gravis treatment market size was valued at USD 1.8 billion in 2024. The market is expected to grow from USD 1.9 billion in 2025 to USD 3.8 billion in 2034, at a CAGR of 7.6%. The rapid surge in the number of myasthenia gravis cases is driving the demand for effective treatment options.
 

For instance, according to the Myasthenia Gravis Foundation of America, approximately 150 to 200 people out of every one million population globally are affected by myasthenia gravis. This high volume of cases is highlighting the urgent need for effective treatment options for disease management and prevention, thereby driving the market growth.
 

In addition, rising awareness towards disease, surging investment into healthcare systems, alongside advancements in diagnostic systems, are boosting the early detection and diagnosis rate of myasthenia gravis, thus, increasing the necessity for its timely treatment. Furthermore, the rapidly increasing elderly population, that is vulnerable to autoimmune disorders, further adds to the prevalence of myasthenia gravis. For instance, according to the United Nations, there were approximately 830 million individuals aged 65 years and older, globally, in 2024. This number was expected to grow substantially to reach 1.7 billion by 2054. Therefore, this rapidly growing aging population, having high risk of myasthenia gravis contraction, is driving the market growth.
 

Furthermore, increasing investments in research and development by pharmaceutical organizations is promoting the development and introduction of advanced treatments such as monoclonal antibodies, corticosteroids, and immunosuppresants for the treatment of myasthenia gravis, further aiding the market growth. For instance, in October 2023, ZILBRYSQ (zilucoplan) developed by UCB, received an approval from the United States FDA in October 2023 for treating myasthenia gravis in adults.
 

Myasthenia Gravis Treatment Market Trends

• The market is witnessing a tremendous shift towards novel advanced treatment options such as FcRn inhibitors and monoclonal antibodies, away from conventional treatments such as immunosuppressants and corticosteroids. Treatments such as efgartigimod (Vyvgart), ravulizumab (Ultomiris), and eculizumab (Soliris) have gained significant market traction due to their limited side effects and long-term relief. The growing introduction of more advanced and novel biologics is expected to supplement this market trend.
   
• A significant growth in investments directed towards the research and development of novel drugs for the treatment of myasthenia gravis has resulted in a surge in the number of ongoing clinical trials. This is further supplemented by the orphan drug designations and fast-track approvals granted by regulatory organizations such as the European Medicines Agency (EMA) and the U.S. FDA.
   
• For instance, in March 2024, the U.S. FDA announced the approval of eculizumab (Soliris), developed and manufactured by AstraZeneca and Alexion Pharmaceuticals, for the treatment of generalized myasthenia gravis (gMG) in patients aged 6 years and older. With this approval, Soliris became the only drug available in the market for the treatment of the condition in the pediatric population.
   
• Furthermore, AI-powered drug repurposing has advanced the discovery of new candidates for Myasthenia Gravis drugs. The development of biologic drugs is undergoing improvement through virtual screening and molecular docking simulations, which is helping to streamline and research and developments activities across the globe.
   

Myasthenia Gravis Treatment Market Analysis

Based on treatment type, the market is segmented into medication, therapy, and surgery. The medication segment is further sub-segmented into cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies. Additionally, the therapy segment is further sub-segmented into intravenous immunoglobulin (IVIG) and plasmapheresis. The medication segment is expected to drive business growth and expand at a CAGR of 7.7%, reaching over USD 2.9 billion by 2034.
 

• The increasing number of cases of myasthenia gravis, globally, is driving the demand for effective treatment options. For instance, according to Johnson & Johnson, myasthenia gravis is estimated to affect approximately 700,000 individuals globally, with around 10-15% of the cases diagnosed in adolescent patients aged between 12 to 17 years. As a result, the demand for developing effective medications for myasthenia gravis treatment is increasing.
   
• Additionally, ongoing research and developments along with increasing availability of monoclonal antibodies indicated for the treatment of myasthenia gravis are driving the segment growth. For instance, in June 2023, the U.S. FDA announced the approval of RYSTIGGO (rozanolixizumab-noli), developed and manufactured by UCB, for the treatment of generalized myasthenia gravis among adult patients.

Based on disease type, the myasthenia gravis treatment market is bifurcated into ocular myasthenia gravis and generalized myasthenia gravis. The generalized myasthenia gravis segment generated revenue of USD 1.3 billion in 2024.
 

• The growing senior population with autoimmune disorders increases the likelihood of developing generalized myasthenia gravis (gMG), highlighting the need for appropriate treatment alternatives. As per the NYU Langone Health August 2021 study, the incidence of autoimmune disorders has grown by 50% among older persons compared to 25 years earlier.
   
• Additionally, regulatory authorities such as the EMA and the U.S. FDA are increasingly granting orphan drug designations, priority review designations, and fast-track approvals for novel treatment options indicated for the treatment of myasthenia gravis. For instance, in January 2025, the U.S. FDA granted priority review designation to nipocalimab, developed and manufactured by Johnson & Johnson, indicated for the treatment of generalized myasthenia gravis.
   

Based on distribution channel, the myasthenia gravis treatment market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment generated a revenue of USD 1 billion in 2024.
 

• The market has witnessed a significant shift towards the adoption of monoclonal antibodies and therapies such as plasmapheresis and intravenous immunoglobulin (IVIG). Hospital pharmacies have made a significant contribution to dispensing these treatments, which often require strict medical supervision. This trend is majorly driving the segment growth.
   
• Additionally, many of the IV treatments and biologic therapies indicated for the treatment of myasthenia gravis are covered by private and government healthcare and insurance plans, highlighting the need for hospital pharmacies as the primary distribution point.

North America: The U.S. myasthenia gravis treatment market was valued at USD 733.3 million in 2024 and is projected to grow substantially in the coming years.
 

• The U.S. FDA is conducting a significant role in promoting the development of novel treatments indicated for the treatment of myasthenia gravis, by granting fast-track approvals, priority review, and orphan drug designations.
   
• For instance, in December 2021, the U.S. FDA announced the approval of Vyvgart (efgartigimod), developed and marketed by Argenx, for the treatment of generalized myasthenia gravis in adult patients. This regulatory support is encouraging pharmaceutical players to develop and introduce novel treatment options, thereby driving the market growth in the region.
   
• Additionally, the U.S. has a significantly advanced healthcare infrastructure, with the presence of major market players such as Alexion Pharmaceuticals, Johnson & Johnson, AbbVie, and Pfizer, promoting the development and commercialization of novel myasthenia gravis treatments, facilitating the market growth.
   

Europe: UK myasthenia gravis treatment market is projected to grow remarkably in the coming years.
 

• Organizations such as Myaware, a charity organization working on myasthenia gravis in the UK, conduct awareness campaigns, early diagnosis programs, and patient education programs. This has led to an increased diagnosis of myasthenia gravis, thereby driving the demand for effective treatment options.
   
• Additionally, regulatory organizations such as the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK provide regulatory support to organizations developing novel treatments for myasthenia gravis.
   
• For instance, in March 2024, the MHRA granted regulatory approval to rozanolixizumab (Rystiggo), developed and commercialized by UCB, for the treatment of generalized myasthenia gravis among adult patients in the UK. Such regulatory approvals are expected to significantly bolster market demand in the UK over the forecast period.
   

Japan holds a commendable position in the Asia Pacific myasthenia gravis treatment market.
 

• According to the World Health Organization (WHO), in 2023, the average life expectancy in Japan was 87.14 years for women and 81.09 years for men, ranking among the highest globally. This longevity has led to a rapidly aging population, with 30% of Japanese citizens aged 65 or older in 2023, as reported by the World Bank Group. As older adults are more prone to autoimmune conditions such as myasthenia gravis, the demand for treatments to ensure preventive care is rapidly growing, thereby driving market growth in the region.
   
• Additionally, regulatory organizations in Japan, such as Japan’s Ministry of Health, Labour and Welfare (MHLW), provide regulatory support to promote the development and commercialization of novel myasthenia gravis treatments, thereby facilitating market growth.
   
• For instance, in January 2022, Argenx announced the approval of VYVGART (efgartigimod alfa) by Japan’s Ministry of Health, Labour and Welfare (MHLW), for the treatment of generalized myasthenia gravis in adult patients.
   

Saudi Arabia in the Middle East and Africa is expected to witness lucrative growth in the myasthenia gravis treatment market.
 

• The increasing expansion of neurological departments in leading healthcare organizations such as the King Saud Medical City and the King Faisal Specialist Hospital and Research Centre, in Saudi Arabia, is promoting the diagnosis and treatment of conditions such as myasthenia gravis. These healthcare organizations also ensure prompt access to advanced treatment options for these conditions, thereby driving market growth in the country.
   
• Additionally, various initiatives by the Saudi government such as the Saudi Vision 2030 have prompted significant domestic and foreign investment in the country’s healthcare infrastructure, resulting in a growing presence of major pharmaceutical companies in the country.
   

Myasthenia Gravis Treatment Market Share

The market is fragmented, featuring multiple pharmaceutical firms having approved products. The top players in this market include Pfizer, UCB pharma, Alexion Pharmaceuticals, and GlaxoSmithKline, which account for approximately 40% of the market share. These players are constantly investing in the development of advanced treatments to enhance myasthenia gravis prevention.
 

Moreover, strategic partnerships with research institutions and healthcare providers have become critical for integrating modern technologies and expanding distribution, which has enabled the companies to address the surge in demand for treatment options. Owing to regulatory support and streamlined approval processes, which further motivate innovation and facilitate market entry, contribute to increased competition in the market. Emerging players are focusing on the development of new treatments that aim to improve disease management. These innovations continue to promote market progression.
 

Myasthenia Gravis Treatment Market Companies

Prominent players operating in the myasthenia gravis treatment industry include:

• AbbVie
• Alexion Pharmaceuticals
• Amgen
• Argenx
• Astellas Pharma
• Bausch Health Companies
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Grifols
• Mitsubishi Tanabe Pharma Corporation
• Novartis
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries
• UCB Pharma

• Alexion Pharmaceuticals is a major and dominant player in the market. The company has captured a significant market share through its Soliris (eculizumab), which was the first complement inhibitor to receive regulatory approval by the U.S. FDA for the treatment of generalized myasthenia gravis. Additionally, the company later introduced products such as Ultomiris (ravulizumab), which is an advanced version of Soliris, for the treatment of myasthenia gravis. Through its advanced products and extensive distribution network, Alexion Pharmaceuticals continues to maintain its market position.
   
• Argenx is another key player in the market of myasthenia gravis treatments. It is a critical innovator in the myasthenia gravis treatment sector, mainly due to its Vyvgart (efgartigimod) FcRn inhibitor treatment indicated for the treatment of generalized myasthenia gravis. The company is expanding globally through increasing regulatory approvals across various regions, backed by the support of strong clinical data.
   
• UCB Pharma is a promising player in the market, due to its enhanced expertise in immunology and neurology research and development. The company constantly conducts clinical trials to introduce novel treatments for patients affected by myasthenia gravis. For instance, the company is currently conducting clinical trials for rozanolixizumab, an FcRn inhibitor, and zilucoplan, a complement C5 inhibitor.
   

Myasthenia Gravis Treatment Industry News:

• In March 2024, the U.S. FDA announced the approval of Soliris (eculizumab), a monoclonal antibody developed by Alexion Pharmaceuticals in partnership with AstraZeneca, for the treatment of generalized myasthenia gravis (gMG) in patients aged 6 years and above. Through this approval, Soliris became the only gMG treatment for pediatric patients with this condition. This approval was expected to significantly expand Alexion Pharmaceuticals’ reach within the myasthenia gravis treatment landscape.
   
• In January 2024, Johnson & Johnson announced that the U.S. FDA granted Priority Review designation for its nipocalimab monoclonal antibody, indicated for the treatment of generalized myasthenia gravis. This designation was expected to promote regulatory support and encourage the development of novel treatment options for myasthenia gravis.
   
• In October 2023, UCB Pharma announced the approval of ZILBRYSQ (zilucoplan), a subcutaneous (SC) targeted peptide inhibitor, by the U.S. FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients. This approval was expected to significantly broaden and strengthen the company’s existing portfolio for myasthenia gravis treatment.
   
• In March 2024, The European Brain Council (EBC) announced the launch of the ‘Rethinking Myasthenia Gravis’ project, in partnership with the Institute of Management of Scuola Superiore de Sant’Anna. It was a research-driven project that would provide policy recommendations to implement real changes to enhance the lives of people living with myasthenia gravis throughout Europe. Such initiatives by organizations are expected to significantly promote diagnosis and treatment for myasthenia gravis.
   

The myasthenia gravis treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medication
  • Cholinesterase inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Monoclonal antibodies 
• Therapy
  • Intravenous immunoglobulin (IVIG)
  • Plasmapheresis
• Surgery

Market, By Disease Type

• Ocular myasthenia gravis
• Generalized myasthenia gravis

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE